8 / 14
Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
Biotech Congress 2018 & Enzymology 2018
March 05-07, 2018
Page 42
Notes:
conference
series
.com
JOINT EVENT
20
th
Global Congress on
Biotechnology
3
rd
International Conference on
Enzymology and Molecular Biology
&
March 05-07, 2018 London, UK
David Rabuka, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C2-090
Developing site-specifically modified ADCs using a chemoenzymatic approach
W
e have developed the SMARTag
TM
technology platform, which enables precise, programmable, site-selective chemical
proteinmodification. Leveraging the target sequence of formylglycine generating enzyme (FGE), we chemoenzymatically
modify proteins to generate a precisely placed aldehyde functionality that can be chemically elaborated. Subsequently, novel
ligation chemistry is employed that exploits this “aldehyde tag” site.Wewill present recent data on our novel proteinmodification
platform and its application to generating novel bioconjugates, including ADCs, utilizing our new conjugation chemistries and
linkers. The application of these chemistries to generate site-specifically modified bioconjugates with improved efficacy and
safety profiles will be presented. Additionally, we will highlight the progress in developing conjugates with a focus on preclinical
studies as well as highlight our progress in cell line development and manufacturing by using this chemoenzymatic approach.
Biography
David Rabuka received a PhD in Chemistry at the University of California, Berkeley as a Chevron Fellow in the Lab of Carolyn Bertozzi. His research included developing
and applying the SMARTagTM platform technology to cell surface modification. Prior to joining Bertozzi’s lab, he worked at the Burnham Institute synthesizing complex
glycans followed by Optimer Pharmaceuticals, where he focused on the development of glycan and macrolide based antibiotics. He was CSO, President and Co-founder
of Redwood Bioscience, where he developed novel protein conjugation methods and biotherapeutic applications such as antibody-drug conjugates. Redwood Bioscience
was acquired by Catalent Pharma Solutions in Oct 2014, where he has continued to apply the SMARTag
TM
technology with various collaborators and partners as a Global
Head of R&D. He graduated with a Double Honors BS in Chemistry and Biochemistry from the University of Saskatchewan, where he received the Dean’s Science Award,
and holds an MS in Chemistry From the University of Alberta. He has authored over 45 major publications, as well as numerous book chapters and holds over 30 patents.
david.rabuka@catalent.comDavid Rabuka
Catalent Biologics, USA